Joshua Resnick, MD Joins SV Life Sciences As Partner

BOSTON, SAN FRANCISCO and LONDON, Jan. 11, 2016 /PRNewswire/ -- SV Life Sciences ("SVLS"), a leading, international life sciences venture capital firm, today announced the appointment of Dr. Joshua Resnick as Partner. He will be based in SVLS' Boston office.

Dr. Resnick joins SVLS' biotech investment team which partners with experienced entrepreneurs and accomplished management teams to develop innovative medicines, technologies and diagnostics that address significant, unmet needs in the medical, health and life sciences industries. Employing deep operating expertise and leveraging strong relationships across the industry, SVLS' team invests along the entire venture spectrum from early stage seed and start-up to late stage development and growth capital.

Dr. Resnick is a highly-regarded life sciences leader, entrepreneur, and investment professional with more than 15 years of experience in investing, company formation, and company leadership across all stages from discovery through commercialization. Before joining SVLS, Dr. Resnick was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund that he established, built and managed within Merck & Co (known as MSD outside the US). Prior to MRL Ventures, Dr. Resnick was a Venture Partner with Atlas Venture, focusing on company formation, seed and Series A investing. During his tenure at Atlas, Dr. Resnick was also the Founder and CEO of two start-ups in the immuno-oncology and neuro spaces. Prior to Atlas Venture, Dr. Resnick was a Partner at Prism Venture Partners, where he focused on early-stage biopharmaceutical, medical device, tools and diagnostics investments. Dr. Resnick is also an Attending Physician at Massachusetts General Hospital as well as Brigham and Women's Hospital, and an Instructor in Medicine at Harvard Medical School. Dr. Resnick graduated Magna Cum Laude from Williams College and received his MD and MBA from the University of Pennsylvania School of Medicine and Wharton School of Business.

"Dr. Resnick brings deep investment leadership experience to SV Life Sciences that immediately expands the biotech capabilities of our firm," said Mike Ross, SVLS Managing Partner and head of the U.S. biotechnology team. "Josh has an extensive track record in sourcing, building and commercializing portfolio companies founded on novel and innovative science that address significant therapeutic gaps in the treatment of serious diseases. Josh's gravitas as a company builder and entrepreneur will be an important asset to SVLS' current and future portfolio company management teams who are the key to our firm's success. We are truly thrilled to announce his joining and to welcome him to our partnership."

Dr. Resnick stated, "I am extremely excited to be joining the SVLS team. Their impeccable reputation, global footprint, and record of innovation drew me to this opportunity. I look forward to bringing my full investment, operating and management experience to the firm's investment efforts."

About SV Life Sciences
SV Life Sciences is a leading, international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the Firm closed its first dedicated life sciences fund in 1994. SVLS' team of 35 professionals is organized according to experience and specialization into three practice areas: Biotechnology, Medical Devices, and Healthcare Services. These individuals' diverse and complementary skill sets and experiences enable SVLS to tailor an investment team for almost any life science business. SVLS employs a close symbiosis between operating and financial professionals which has led to significant success over five investment funds. SVLS has offices in Boston, London and San Francisco. For more information, please visit the company's website at http://www.svlsa.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/joshua-resnick-md-joins-sv-life-sciences-as-partner-300201855.html

SOURCE SV Life Sciences